Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 0.84 |
| ▸ | MMP13 | P45452 | 20/20 | 0.84 |
| ▸ | MMP14 | P50281 | 3/20 | 0.84 |
| ▸ | MMP9 | P14780 | 2/20 | 0.84 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.84 |
| ▸ | MMP1 | P03956 | 1/20 | 0.71 |
| ▸ | MMP3 | P08254 | 1/20 | 0.71 |
| ▸ | MMP7 | P09237 | 1/20 | 0.71 |
| ▸ | MMP8 | P22894 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13314496 | 1.00 | MMP2 (0.84) | MMP2MMP13MMP14MMP9ADAMTS4 | |
| SCHEMBL13314499 | 0.92 | MMP2 (0.89) | MMP2MMP13MMP14MMP9ADAMTS4 | |
| SCHEMBL3610523 | 0.92 | MMP2 (0.89) | MMP2MMP13MMP14MMP9ADAMTS4 | |
| SCHEMBL3608983 | 0.92 | MMP2 (0.71) | MMP2MMP13MMP14MMP9ADAMTS4 | |
| SCHEMBL3610357 | 0.92 | MMP2 (1.00) | MMP2MMP13MMP14MMP9ADAMTS4 | |
| SCHEMBL13314471 | 0.92 | MMP2 (1.00) | MMP2MMP13MMP14MMP9ADAMTS4 | |
| SCHEMBL13314465 | 0.92 | MMP2 (1.00) | MMP2MMP13MMP14MMP9ADAMTS4 | |
| SCHEMBL3613470 | 0.91 | MMP2 (0.86) | MMP2MMP13MMP14MMP9ADAMTS4 | |
| SCHEMBL13314497 | 0.91 | MMP2 (0.86) | MMP2MMP13MMP14MMP9ADAMTS4 | |
| SCHEMBL3616707 | 0.90 | MMP2 (0.83) | MMP2MMP13MMP14MMP9ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | claimed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | claimed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| US-7645574-B2 | Providing palladium ions, contacting ions and nucleic acids under conditions effective to bind palladium on one or more sites of the nucleic acid, contact with nickel or nickel alloy under conditions effective to deposit nickel or nickel alloy on nucleic acid, attach/immobilize to solid support; biochip | INTEGRATED NANO-TECHNOLOGIES, LLC (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| WO-2006113457-A1 | POLYMER-FLUOROSURFACTANT ASSOCIATIVE COMPLEXES | THE CLOROX COMPANY (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| US-20040229247-A1 | Providing palladium ions, contacting ions and nucleic acids under conditions effective to bind palladium on one or more sites of the nucleic acid, contact with nickel or nickel alloy under conditions effective to deposit nickel or nickel alloy on nucleic acid, attach/immobilize to solid support; biochip | ENPLAS AMERICA, INC. | 2004-11-18 | — | — | US | disclosed |
| WO-2004096986-A2 | METHOD FOR QUANTITATIVE DETECTION OF NUCLEIC ACID MOLECULES | INTEGRATED NANO-TECHNOLOGIES, LLC (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004065570-A2 | METHODS OF METALLIZING NUCLEIC ACID MOLECULES AND METHODS OF ATTACHING NUCLEIC ACID MOLECULES TO CONDUCTIVE SURFACES | INTEGRATED NANO-TECHNOLOGIES, LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| US-3932610-A | SURFACTANTS, SOLVENTS, HAIR GROOMING AGENTS | LEVER BROTHERS COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | MMP2 5/4885MMP13 13/4885MMP14 19/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | MMP2 5/4885MMP13 13/4885MMP14 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.